In a related approach, Liang et al. developed a trained immunity-related vaccine (TIrV) based on OMV nanohybrids (OMV-SIRPα@CaP/GM-CSF) that did not rely on tumour-specific antigens. The gene discussed is SIRPA; the disease is neoplasm.